As recomendações para CDI nos pacientes idosos são semelhantes às indicações gerais de desfibrilador, desde que o paciente apresente expectativa de vida maior que um ano91:
Grau de recomendação I:
a) Ressuscitados de FV/TV ou de TV monomórfica hemodinamicamente instável de causa não reversível FE ≤ 35% (NE A).
b) TV sustentada com comprometimento hemodinâmico em portador de cardiopatia estrutural e FE ≤ 35% (NE A).
c) Prevenção primária em portadores de infarto do miocárdio há mais de 40 dias com importante comprometimento da função ventricular, FE ≤ 35% e classe funcional II e III, ou FE ≤ 30% e CF I, II, III (NE A).
d) FE ≤ 40%, TVNS espontânea e TVS indutível ao EEF (NE B).
Grau de recomendação IIa:
a) TV sustentada com comprometimento hemodinâmico em portador de cardiopatia estrutural e FE ≤ 35% (NE A).
b) Prevenção secundária em pacientes recuperados de PCR de causa não reversível, com FE ≥ 35% (NE A).
c) Síncope de origem indeterminada com indução de TVS hemodinamicamente instável (NE B).
d) Prevenção primária em pacientes com cardiomiopatia dilatada não isquêmica, CF II-III, com FEVE ≤ 35% e expectativa de vida de pelo menos um ano (NE A).
e) Prevenção primária em pacientes com cardiopatia isquêmica ou não isquêmica, CF III-IV, FEVE ≤ 35%, QRS ≥ 120 ms, para os quais tenha sido indicado TRC e expectativa de vida de pelo menos um ano (NE B).
Grau de recomendação III:
a) Presença de cardiopatia passível de correção cirúrgica ou percutânea (NE B).
b) Presença de cardiopatia isquêmica e FEVE ≥ 35% (NE B). c) Presença de taquicardia ventricular incessante (NE C).
1. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, VierKant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 31: 150-7.
2. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol. 1999; 84: 13R-138R.
3. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271: 840-4.
4. R a j a l a A S , G e i g e r U K , H a a v i s t o M V, K a l t i a l a K S , M a t t i l a K J. Electrocardiogram, clinical findings and chest x-ray in persons aged 85 years or older. Am J Cardiol. 1985; 55: 1175-8.
5. Kantelip JP, Sage E, Duchene-Marullaz P. Findings on ambulatory electrocardiographic monitoring in subjects older than 80 years. Am J Cardiol. 1986; 57: 398-401.
6. Manolio TA, Furberg CD, Rautaharju PM,Siscovick D, Newman AB, Borbani NO, et al.. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol. 1994; 23: 916-25.
7. Fleg JL, Kennedy HL. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects greater than or equal to 60 years of age. Am J Cardiol. 1992; 70: 748-51.
8. Wei JY. Mechanisms of disease: age and the cardiovascular system. N Engl J Med. 1992; 327: 1735-9.
9. Lakatta EG. Cardiovascular regulatory mechanism in advanced age. Physiol Rev. 1993; 73: 413-67.
10. Ruoke GA. Autonomic and cardiovascular function in the geriatric patient. Anesthesiol Clin North Am. 2000; 18: 31-46.
11. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984; 69: 250-8.
12. Crawford MH, Bernstein SJ, Deedwania PC, DiMarco JP, Ferrick KJ, Garson Jr A, et al. ACC/AHA guidelines for ambulatory electrocardiography: a reporto of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, develope in collaboration with the North American Society for Pacing and Eletrophysiology. J Am Coll Cardiol. 1999; 34: 912-48.
13. DiMarco JP, Philbrik JP. Use of ambulatory electrocardiographic (Holter) monitoring. Ann Intern Med. 1990; 113: 53-68.
14. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, et al. Guidelines on management (diagnosis and treatment) of syncope-- update 2004. Europace. 2004; 6 (6): 467-537.
15. Fitzpatrick A, Sutton R. Tilting towards a diagnosis in recurrent unexplained syncope. Lancet. 1989; 1 (8639): 658-60.
16. Del Rosso A, Ungar A, Bartoli P, Cellai T, Mussi C, Marchionni N, et al. Usefulness and safety of shortened head-up tilt testing potentiated with sublingual glyceryl trinitrate in older patients with recurrent unexplained syncope. J Am Geriatr Soc. 2002; 50 (8): 1324-8.
17. Natale A, Sra J, Akhtar M, Kusmirek L, Tomassoni G, Leonelli F, et al. Use of sublingual nitroglycerin during head-up tilt-table testing in patients > 60 years of age. Am J Cardiol. 1998; 82 (10): 1210-3.
18. de Castro RR, da Nobrega AC. Elderly patients with unexplained syncope: what should be considered a positive tilt test response? Auton Neurosci. 2006; 126-127: 169-73.
19. Rose KM, Eigenbrodt ML, Biga RL, Couper DJ, Light KC, Sharrett AR, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006; 114 (7): 630-6.
20. Munro NC, McIntosh S, Lawson J, Morley CA, Sutton R, Kenny RA. Incidence of complications after carotid sinus massage in older patients with syncope. J Am Geriatr Soc. 1994; 42 (12): 1248-51.
21. Brady PA, Shen WK. When is intracardiac electrophysiologic evaluation indicated in the older or very elderly patiente? Complications rate and data. Clin Geriatr Med. 2002; 18: 339-60.
22. Zado ES, Callans DJ, Gottlieb CD, Kutalek SP, Wilbur SL, Samuels FL, et al. Efficacy and safety of catheter ablation in Octogenarians. J Am Coll Cardiol. 2000; 35: 458.
23. Sociedade Brasileira de Cardiologia. Diretrizes para avaliação e tratamento de pacientes com arritmias cardíacas Parte II - avaliação eletrofisiológica invasiva de pacientes com arritmias cardíacas. Arq Bras Cardiol. 2002; 79 (suplemento 5): 17.
24. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. Circulation. 1995; 92: 673-91.
25. Kapoor WN, Karpf M, Wieand S, Peterson JR, Levey GS. A prospective evaluation and follow-up of patients with syncope. N Engl J Med. 1983; 309: 197-204.
26. Guidelines on management (diagnosis and treatment) of syncope-update 2004. (Executive Summary) Eur Heart J. 2004; 25: 2054-72.
27. Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (Executive Summary). Eur Heart J. 2006; 27: 2099-140.
28. Kappor WN. Syncope. N Engl J Med. 2000; 343 (25): 1856-62. 29. Lipsitz L, Grubb BP. Syncope in the elderly. In: Grubb BP, Olshansky B.
(eds). Syncope: mechanisms and management. 2nd. ed. Blackwell Futura Publishing; 2005. p. 301-14.
30. Savage DD, Corwin L, McGee DL, Kannel WB, Wolf PA. Epidemiologic features of isolated syncope: the Framingham Study. Stroke. 1985; 16: 626-9. 31. Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, et al.
Incidence and prognosis of syncope. N Engl J Med. 2002; 347: 878-85. 32. Lipsitz LA, Wei JY, Rowe JW. Syncope in elderly institutionalized population:
prevalence, incidence and associated risk. QJM. 1985; 55: 45-55. 33. Smith JJ, Hughes CV, Ptacin MJ, Barney JA, Tristani FE, Ebert TJ. The effect
of age on hemodynamic response to graded postural stress in normal men. J Gerontol. 1987; 42: 406-11.
34. Taylor JA, Hand GA. Sympathoadrenalcirculatory regulation of arterial pressure during orthostatic stress in young and older man. Am J Physiol. 1992; 263: R1147-55.
35. Mayhan WG; Faraci FM; Baumbach GL, Heistad DD. Effects of aging on responses of cerebral arterioles. Am J Physiol. 1990; 27: H1138-H1143. 36. Kaufmann H. Syncope: a neurologist viewpoint. Cardiol Clin. 1997; 15:194. 37. Jansen RM; Connelly M; Kelley M, et al. Postprandial hypotension in elderly
patients with unexplained syncope. Arch Intern Med. 1995; 155: 945-52. 38. Morley CA, Sutton R. Carotid sinus syncope. Int J Cardiol. 1984; 6: 287-93. 39. Wagshal AB, Huang SKS. Carotid sinus hypersensitivity. In: Grubb BP,
Olshansky B (eds). Syncope: Mechanisms and Management. Armonk, NY: Futura Publishing Co; 1998. p. 73-106.
40. Kapoor WN, Smith MA, Miller NL. Upright tilt testing in evaluating syncope: a comprehensive literature review. Am J Med. 1994; 97: 78-87. 41. Gubb BP. Neurocardiogenic syncope. In: Grubb BP, Olshansky B (eds).
Syncope: Mechanisms and Management. Armonk, NY: Futura Publishing Co; 1998. p. 73-106.
42. Hachul D, Sosa EA, Consolim F, Magalhães L, Scanavacca M, Martineli M, et al. Valor diagnóstico do teste de inclinação na avaliação da síncope de origem indeterminada. Resultados preliminares. Arq Bras Cardiol. 1994; 62 (1): 7-9.
43. Lipsitz LA, Marks ER, Koestner JS. Reduced susceptibility to syncope during postural tilt in old age: is beta-blockade protective? Arch Intern Med. 1989;
149: 2709-12.
44. Fuster V, Rydén LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbagen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e-196.
45. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators. Stroke. 2009; 40: 1410-6.
46. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. and Active Investigators. Benefit of oral anticoagulant over therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118: 2029-37.
47. Eckman MR, Rosand J, Groemberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin with nonvalvular atrial fibrillation. Ann Intern Med. 2009; 150 (2): 73-83.
48. Gage BF, Waterman AD,Shammon W, Boechler M, Rich MW, Radford MJ. Validation of clinical calcification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-70. 49. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients
with atrial fibrillation. N Engl J Med. 2009; 360 (20): 2127-9.
50. Zado ES, Callans DJ, Gottlieb CD, Kutalek SP, Wilbur SL, Samuels FL, et al. Efficacy an safety of catheter ablation inoctogenarians. J Am Coll Cardiol. 2000; 35: 458-62.
51. Da Costa A, Thevenin J, Roche F, Romeyer-Bouchard C, Abdellaoui L, Messier M, et al. Results from the Loire-Ardeche-Drome-Isere- Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation. 2006; 114: 1676-81.
52. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659-66.
53. Bhargava M, Marrouche NF, Martin DO, Schweikert RA, Saliba W, Saad EB, et al. Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled-tip ablation catheter. J Cardiovasc Electrophysiol. 2004; 15: 8-13.
54. Kusumoto F, Prussak K, Wiesinger M, Pullen T, Lynady C. Radiofrequency catheter ablation of atrial fibrillation in older patients: outcomes and complications. J Interv Card Electrophysiol. 2009.
55. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet. 1997; 350: 1417-24.
56. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden cardiac death in heart failure trial (SCDHeFT) Investigators. Amiodarone or an Implantable Cardioverter-defibrillator for Congestive Heart Failure. N Engl J Med. 2005; 352: 225-37.
57. A Comparison of Antiarrythmic-drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-fatal Ventricular Arrythmias. The Antiarrythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997; 337: 1576-83.
58. Connolly SJ, Gent M, Roberts RS, Donian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the Implantable Cardioverter Defibrillator against Amiodarone. Circulation. 2000; 101: 1297-302.
59. Huan DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ, et al. Improval survival associated with prophylactyc implantabel desfibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: A MADTI-II Substudy. J Cardiovasc Electrpophysiology. 2007; 8: 833-8.
60. Ermis C, Zhu AX, VanHeel L, Sakaguchi S, Lurie KG, Benditt DG.
Comparison of ventricular arrythmia burden, therapeutic interventions, and survival, in patients < 75 and > 75 years of age treated with implantable cardioverter defibrillators. PACE. 2007; 9: 270-4.
61. Moss AJ. Treatment of arrythmias an use of implantable cardioverter- defibrillators to improve survival in elderly with cardiac disease. Clin Geriatr. 2007; 23: 205-19.
62. Aronow WS. Treatment of ventricular arrythmias in the elderly. Geriatrics. 2008; 8: 20-8.
63. Hohnloser SH, Klingenheben T, Zabel M, Schoppert M, Mauss O. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial inarction in the thrombolitic era. J Am Coll Cardiol. 1999; 33: 1895-902.
64. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 913.
65. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial) randomized controlled trial. Lancet. 2003; 362: 14-21.
66. Julian DJ, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet. 1982; 1: 1142-7. 67. Aronow WS. Treatment of ventricular arrhythmias in the elderly. Geriatrics.
2008; 63: 20-8.
68. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet. 1997; 350: 1417-24.
69. Bardy GH, Lee KL, Mark DB, Poole, JE, Packer DL, Boineau R, et al. Sudden cardiac Death in Heart Failure Trial (SCDHeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225–37.
70. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhymias. Electrophysiologic Study versus Electrocardiographic. Monitoring Investigators. N Engl J Med. 1993; 329: 452-8.
71. Greene HL: The CASCADE Study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seathle. CASCADE Investigators. Am J Cardiol. 1993; 72: 70F-74F.
72. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997; 337: 1576-83.
73. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000; 21: 2071- 8.
74. Fleg J, Kennedy H. Cardiac arrhythmias in a healthy elderly population: detection by 24- hour ambulatory electrocardiography. Chest. 1982;81; 302-7.
75. Frishman WH, Heiman M, Karpenos A, Qoi WL, Mitzner A, Goldkom R, et al. Twentyfour hour ambulatory electrocardiography in elderly subjects: Prevalence of various arrhythmias and prognostic implications. Am Heart J. 1996; 132: 297-302.
76. Arritmias cardiacas en los ancianos. Lasses y Ojeda LA. Archivos de Cardiologia de México 2002; 72: S106-S110.
77. Wenger N, Helmy T Patal A, Hanna I. Approaching Cardiac Arrhythmias in the Elderly Patient. Medscape General Medicine. 2005; 7: 24.
78. Schmidt B, Brunner M, Olschewski M, et al. Pacemaker therapy in very elderly patients: long-term survival and prognostic parameters. Am Heart J. 2003; 146: 908-13.
79. Vassolo M, Lamas GA. Dual-chamber vs ventricular pacing in the elderly: quality of life and clinical outcomes. Eur Heart J. 1999; 20: 1607-8.